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OBJECTIVE: To examine the association of atherogenic and thrombogenic markers and lymphotoxin-alfa gene
mutations with the risk of premature coronary disease.
METHODS: This cross-sectional, case-control, age-adjusted study was conducted in 336 patients with premature
coronary disease (,50 years old) and 189 healthy controls. The control subjects had normal clinical, resting, and
exercise stress electrocardiographic assessments. The coronary disease group patients had either angiographi-
cally documented disease (.50% luminal reduction) or a previous myocardial infarction. The laboratory data
evaluated included thrombogenic factors (fibrinogen, protein C, protein S, and antithrombin III), atherogenic
factors (glucose and lipid profiles, lipoprotein(a), and apolipoproteins AI and B), and lymphotoxin-alfa
mutations. Genetic variability of lymphotoxin-alfa was determined by polymerase chain reaction analysis.
RESULTS: Coronary disease patients exhibited lower concentrations of HDL-cholesterol and higher levels of
glucose, lipoprotein(a), and protein S. The frequencies of AA, AG, and GG lymphotoxin-alfa mutation
genotypes were 55.0%, 37.6%, and 7.4% for controls and 42.7%, 46.0%, and 11.3% for coronary disease
patients (p=0.02), respectively. Smoking, dyslipidemia, family history, and lipoprotein(a) and lymphotoxin-alfa
mutations in men were independent variables associated with coronary disease. The area under the curve (C-
statistic) increased from 0.779 to 0.802 (p,0.05) with the inclusion of lipoprotein(a) and lymphotoxin-alfa
mutations in the set of conventional risk factors.
CONCLUSIONS: The inclusion of lipoprotein(a) and lymphotoxin-alfa mutations in the set of conventional risk
factors showed an additive but small increase in the risk prediction of premature coronary disease.
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& INTRODUCTION
Coronary atherosclerosis and its complications constitute
a complex and polygenic disorder resulting from the
combined effects of multiple environmental and genetic
factors (1). Several traditional risk factors increase the risk of
coronary heart disease (CHD) and heart attack (2-4).
Coronary artery disease (CAD) results from the progression
of atherosclerotic plaque. Studies show that almost half of
an individual’s susceptibility to CAD is heritable (3). Lipid
metabolism and inflammation have been identified as main
biological pathways in the pathogenesis of CAD. Arterial
inflammation is a key component of plaque progression and
plaque rupture, with atherosclerotic lesions established as
active sites of inflammation (4). Biomarkers, coagulation
factors, and proteins appear to coordinate the development
of atherosclerosis and lead to the formation of complex
atherosclerotic plaques and thrombus formation (5-7).
Several biomarkers and cytokines likely play a role in
determining the degree of inflammation and contribute to
the promotion or retardation of atherothrombosis develop-
ment. Despite the improved understanding of atherothrom-
bosis pathophysiology, the conventional CAD risk factors
do not fully account for the overall CAD risk (8,9).
Moreover, risk factors associated with premature CAD are
poorly recognized. Studies also show conflicting results
with respect to some atherogenic and thrombogenic
biomarkers of CAD (10-12). Genetic influence is often
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suggested as an important factor associated with the risk of
premature CAD (13). The proinflammatory cytokine lym-
photoxin-alfa (LTA) is a key mediator of the initiation of
local vascular inflammatory responses. The actions of LTA
are characterized by the stimulation of adhesion molecule
production, thrombogenesis, smooth muscle proliferation,
platelet activation, release of vasoactive agents (14-17), and
control of nitric oxide production (8). Functional single
nucleotide polymorphisms (SNPs) in the LTA gene have
been found to be associated with MI in the Japanese
population (17,18). However, other researchers failed to
provide evidence of the relationship between LTA and CAD
(19-21). The mutant allele results in significantly increased
production of LTA in mononuclear cells stimulated in vitro,
which is related to increased gene transcription (17). The
aim of this study was to investigate whether traditional risk
factors, thrombogenic and atherogenic biomarkers, and the
mutation A252G in the LTA gene may be related to an
increased predisposition to premature CAD and its interac-
tion with traditional risk factor modulation.
& MATERIALS AND METHODS
Study population
A cross-sectional, case-control, age-matched study was
conducted in 525 consecutive subjects ,50 years of age.
Clinical characteristics and laboratory data were analyzed in
189 healthy control individuals and in 336 patients with
documented premature stable CAD (,50 years of age)
selected from the outpatient clinic of the Heart Institute
(InCor), Faculdade de Medicina da Universidade de Sa˜o
Paulo, Brazil. We hypothesized that young adult patients
exhibit a larger proportion of CAD driven by genetic risk
factors compared with older patients with CAD. The control
group with no CAD included healthy subjects with normal
clinical histories, physical examinations, and resting and
exercise stress electrocardiographic assessments. The CAD
group included outpatients from the Heart Institute (InCor)
with angiographically documented disease (.50% luminal
reduction) and patients with a previous myocardial infarct
episode. The local institutional review boards approved the
study protocol, and written informed consent was obtained
from each study participant.
Data collection
The clinical data obtained included age, gender, body mass
index (weight [kg]/height [m2]), smoking history, arterial
hypertension, diabetes, dyslipidemia, previous myocardial
infarction, and family history of premature CAD. Smokers
who had quit more than 1 year prior to the study were
considered ex-smokers. Current and former smokers were
considered as one group andwere comparedwith the patients
who had never smoked. Hypertension was defined as a
systolic blood pressure$140 mmHg, diastolic blood pressure
$90 mm Hg, or both measured at study entry or following
antihypertensive treatment. A family history of CAD was
defined as obstructive CAD occurring in parents (before age
55 for men and 65 for women) and siblings. Dyslipidemia was
considered as the presence of hypercholesterolemia (total
cholesterol .6.2 mmol/L) or hypertriglyceridemia (triglycer-
ides .2.87 mmol/L) with medication use (e.g., fibrates and
statins). Diabetes was diagnosed when a patient was taking
hypoglycemic drugs or exhibited fasting glucose blood levels
.7.0 mmol/L. No patients used contraceptives or hormone
replacement therapy. Thrombogenic factors (fibrinogen,
assessed by the Clauss method; protein C, protein S, and
antithrombin III, assessed by chromogenic methods); and
atherogenic factors (fasting glucose and lipid profiles,
assessed by standard protocols; and lipoprotein (a) and
apolipoprotein AI and B fractions, assessed using the
immunoturbidimetric method) were determined.
Genotyping
Genomic DNA was extracted from peripheral blood
leukocytes by the standard salting-out procedure (10). We
studied SNP 252A.G (rs909253) in the LTA gene, which
encodes LTA on Chromosome 6p21 in intron 1 (11). The
genetic variability of LTA was determined by amplification of
the genomic DNA using polymerase chain reaction (PCR)
followed by the restriction fragment length polymorphism
(RFLP) technique. A 30-cycle PCR was performed in a PTC-
DNA Engine Tetrad2 (MJ Research, Waltham, Massachusetts,
USA) using a 10-mL reactive solution containing 10 mM Tris-
HCl (pH 9.0), 50 mM KCl, 2.5 mM MgCl2, 100 mM of each
dNTP, 0.3 U of Easy Taq DNA Polymerase, 5 pmol of each
primer, and 1 mL of genomic DNA template. PCR products
were digested with 1 U of NcoI restriction enzyme and
visualized using 2.5% agarose gel electrophoresis. The
presence of the 782-pb fragments indicated homozygosis of
the wild allele (AA), while the presence of the 586- and 196-pb
products indicated homozygosis of the mutant allele (GG) and
the presence of 782-, 586-, and 196-pb products indicated
heterozygosis (AG genotype). Genotype distribution was in
Hardy-Weinberg equilibrium in all study samples (p.0.001).
Statistical methods
The Hardy Weinberg equilibrium for the distribution of
genotypes was estimated by the chi-square test in the
groups studied (no-CAD and CAD). Chi-square tests, t tests,
and analysis of variance with Tukey’s correction for multi-
ple comparisons were used for baseline comparisons. The
odds ratios for different association models were calculated
with a 95% confidence interval (CI) by multiple logistic
regressions with confounders determined by a backward
conditional elimination method for a significance level
below 0.05. Logistic regression was used to estimate the
cross-sectional association of the traditional risk factors for
CAD with the following independent variables: gender,
smoking status, family history of premature CAD, diabetes,
dyslipidemia, history of arterial hypertension, Lp(a), and
LTA polymorphisms. Lp(a) was dichotomized into normal
(,30 mg/dL) and high ($30 mg/dL) values. CAD was the
dependent variable. To evaluate the model’s performance, a
receiver operating characteristic (ROC) curve was devel-
oped, and the area under the ROC curve (AUC or C-
statistic) was used to measure the discriminative power. The
C-statistic for the clinical model and the biomarker
information added to the clinical model were compared.
The significance level adopted for the statistical tests was
5% (p,0.05). Statistical analyses were performed using the
SAS for Windows (Statistical Analysis System) program,
version 9.2 (SAS Institute Inc., 1989-1996, Cary, NC, USA).
& RESULTS
Baseline characteristics
The demographic and laboratory characteristics of the
study population are shown in Table 1.
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Females, smokers, and individuals with hypertension,
diabetes, dyslipidemia, and a family history of CAD were
significantly more prevalent in the CAD group. Compared
with the controls, the CAD patients exhibited significantly
lower plasma concentrations of HDL-cholesterol (p,0.001)
and higher levels of fasting glucose (p= 0.005), lipoprotein
(a) (p,0.001), and protein S (p= 0.038). The genotypic
frequency distributions of the LTA A252G polymorphism
Table 1 - Demographic and laboratory characteristics of the study population.
All patients N=525 Controls N=189 (36%)
Coronary artery disease
patients N=336 (64%) p-value
Age (years) 40.4¡5.3 40.7¡5.9 40.2¡5.0 0.275
Women (%) 271 (51.6) 69 (36.5) 202 (60.1) ,0.001
Hypertension 150 (28.6) 33 (17.5) 117 (34.8) ,0.001
Smokers 56 (10.7) 7 (3.7) 49 (14.6) ,0.001
Diabetes 87 (16.6) 23 (12.2) 64 (19.2) 0.039
Dyslipidemia 298 (56.9) 83 (43.9) 215 (64.2) ,0.001
Family history of CAD 255 (48.8) 33 (17.5) 222 (66.5) ,0.001
Body mass index (kg/m2) 25.4¡5.8 24.9¡5.4 25.6¡6.0 0.235
Leukocytes (mm3) 6647¡1747 6467¡1632 6753¡1806 0.080
Platelets (mm3) 181,730¡112,077 178,784¡102,551 183378¡117185 0.641
Cholesterol (mg/dL) 115.5¡64.2 114.0¡49.4 116.4¡71.3 0.656
HDL-cholesterol (mg/dL) 42.1¡13.3 45.7¡13.0 40.0¡13.0 ,0.001
LDL-cholesterol (mg/dL) 69.3¡34.4 65.7¡27.4 71.5¡37.8 0.098
Triglycerides (mg/dL) 127.5¡213.0 106.6¡122.4 138.8¡248 0.078
Glucose (mg/dL) 96.1¡32.3 91.0¡11.2 99.2¡39.7 0.005
Creatinine (mg/dL) 0.74¡0.21 0.74¡0.16 0.74¡0.24 0.688
Uric acid (mg/dL) 5.4¡2.1 5.2¡2.6 5.5¡1.8 0.109
Apolipoprotein A1 (mg/dL) 0.43¡0.26 0.42¡0.22 0.44¡0.27 0.544
Apolipoprotein B (mg/dL) 0.65¡0.28 0.61¡0.28 0.67¡0.25 0.037
C-reactive protein (mg/dL) 6.54¡17.7 4.80¡13.7 7.5¡19.5 0.064
Fibrinogen (g/L) 291.9¡144.5 297¡134.1 289¡150.1 0551
Lipoprotein (a) (mg/dL) 39.0¡41.2 31.4¡32.1 43.3¡45.0 ,0.001
Protein-S % 72.1¡22.0 63.4¡23.0 73.0¡21.7 0.038
Protein-C % 66.3¡26.6 63.2¡29.6 66.6¡26.2 0.537
Antithrombin III % 80.1¡18.5 80.4¡26.4 80.1¡17.8 0.966
Factor V activity % 49.9¡37.5 49.7¡38.3 49.9¡37.0 0.953
Table 2 - Clinical and biochemical data of all subjects according to the genotype of the LTA 252A.G polymorphism.
LTA 252A.G AA N=247(47.1) AG N=225(42.9) GG N=52(10) p-value
Age (years) 40.4¡5.3 40.8¡5.4 40.1¡5.1 0.274
Women (%) 120(48.6) 127(56.4) 24(44.2) 0.126
Hypertension 58(23.5) 74(32.9) 17(32.7) 0.060
Smokers 100(40.5) 96(42.7) 19(37.2) 0.749
Diabetes 37(15.1) 39(17.3) 11(21.1) 0.533
Dyslipidemia 135(54.7) 131(58.5) 32(61.5) 0.551
Family history of CAD 116(47.3) 107(47.8) 32(61.5) 0.159
Coronary artery disease 143(57.9) 154(68.4) 38(73.1) 0.021
Body mass index (kg/m2) 25.8¡6.2 25.4¡5.7 24.0¡4.4 0.181
Leukocytes (mm3) 6723¡1711 6524¡1767 6863¡1811 0.329
Platelets (mm3) 186,313¡118,890 176,638¡103,955 182,634¡114,614 0.646
Cholesterol (mg/dL) 114.9¡66.7 116.6¡61.7 115.6¡63.6 0.960
HDL-cholesterol (mg/dL) 43.7¡13.3 40.8¡12.5* 40.2¡15.8 0.038
LDL-cholesterol (mg/dL) 67.2¡34.3 72.3¡34.8 66.7¡33.4 0.379
Triglycerides (mg/dL) 137.0¡289.5 113.5¡108.0 150.1¡151.2 0.446
Glucose (mg/dL) 96.0¡32.2 95.7¡30.4 98.4¡40.6 0.913
Creatinine (mg/dL) 0.76¡0.18 0.72¡0.24* 0.73¡0.20 0.133
Uric acid (mg/dL) 5.5¡2.3 5.4¡1.9 5.1¡1.9 0.519
Apolipoprotein A1 (mg/dL) 0.43¡0.25 0.44¡0.26 0.42¡0.27 0.793
Apolipoprotein B (mg/dL) 0.66¡0.27 0.63¡0.26 0.64¡0.23 0.575
C-reactive protein (mg/dL) 5.5¡15.0 5.8¡12.4 12.0¡32.0** 0.030
Fibrinogen (g/L) 292.2¡143.4 283.6¡145.2 323.1¡144.8 0.211
Lipoprotein(a) (mg/dL) 40.2¡39.8 37.8¡39.8 38.9¡52.9 0.816
Protein-S % 70.8¡21.7 73.3¡21.5 72.2¡24.9 0.683
Protein-C % 66.8¡28.5 67.8¡24.4 56.9¡26.5 0.172
Antithrombin III % 79.8¡20.0 81.3¡16.5 77.1¡19.6 0.517
Factor V activity % 52.8¡37.6 45.5¡37.3* 53.8¡36.3 0.107
Values in parenthesis are percentages. *HDL (AA vs. AG), p=0.020; creatinine (AA vs. AG), p=0.046; FV (AA vs. AG), p=0.048; ** C-reactive protein (AA vs.
GG), p=0.010, and (AG vs. GG), p=0.014.
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for A/A homozygotes, A/G heterozygotes, and G/G
homozygotes were 47.1%, 42.9, and 10% for all subjects;
55.0%, 37.6%, and 7.4% for the control group; and 42.7%,
46.0%, and 11.3% for the patient group, respectively
(p= 0.021). The frequencies of the A and G alleles of the
LTA gene were 68.6% and 31.4% among the 524 individuals
in the entire population; 73.8% and 26.2% in the controls;
and 65.7% and 34.3% in the CAD group, respectively.
Genotyping distributions in both the control and CAD
groups were consistent with Hardy-Weinberg equilibrium.
No association was observed between LTA A252G and
traditional risk factors. HDL-cholesterol and C-reactive
protein plasma levels were higher in the AA (p= 0.038) and
GG genotype subjects (p= 0.030), respectively. A multivariate
logistic regression analysis showed that smoking (OR 4.81;
95% CI 1.98 – 11.7, p= 0.001), dyslipidemia (OR 2.35; 95% CI
1.10 – 5.05, p= 0.028), family history of CAD (OR 8.20; 95% CI
4.692 - 12.103, p,0.001), and Lp(a) (OR 1.29; 95% CI 1.01 -
1.65, p= 0.042) and LTA (OR 3.38; 95% CI 1.03 – 11.10,
p= 0.007) mutations in men, but not in women (OR 1.34; 95%
CI 0.49 – 3.63, p= 0.567), were independent factors associated
with CAD (Figure 1). The performances of the predictive risk
models are shown in the ROC curves (Figure 2). Model1
included the clinical variables gender, hypertension, smok-
ing, diabetes, family history of CAD, dyslipidemia, and body
mass index. The AUC (C-statistic) of this model for the
prediction of CAD in patients,50 years old was 0.779. There
was a progressive increase in the AUC with the inclusion
of the Lp(a) and Lp(a) + LTA mutation variables of
0.796 (p=0.047, for comparisons between model1 and
model1+Lp(a)) and 0.802 (p=0.024, for comparisons between
model1 and model1+Lp(a)+LTA mutation).
& DISCUSSION
Our study shows that Lp(a) and LTA mutations in men
are associated with premature CAD. Lp(a) and LTA
mutations exhibit an additive effect on the C-statistic AUC
for the traditional risk factors. Several studies have shown
conflicting results regarding the association between spe-
cific biomarkers and the prediction of CAD (22-27).
Lipoprotein (a) and risk prediction for CAD
In a nested case-control study, Kim et al. (28) analyzed 18
biomarkers previously associated with CAD in 321 patients
with CAD and 743 control postmenopausal women. Five
(vWF, factor VIII, homocysteine, IL-6, and D-dimer) of the
18 biomarkers tested were associated with CAD, but only D-
dimer improved the C-statistic compared with traditional
risk factors. Contrary to our results, Lp(a) was not
associated with CAD, but the previous study included only
women who were older (aged between 50 and 79 years)
than our patients. Blakenberg et al. (29) analyzed the risk
prediction of CAD associated with 30 biomarkers in 2
middle-aged European populations. The study analyzed
Lp(a) and other biomarkers and showed that no biomarker
improved risk estimation in either population. The structure
of lipoprotein (a) is similar to the structure of LDL
cholesterol, which includes one additional plasminogen-
like glycoprotein, namely apolipoprotein (a). Due to these
characteristics, this particle may contribute to the processes
of atherogenesis and thrombogenesis. Lp(a) studies showed
conflicting results regarding the risk prediction of CAD (30-
34). Bennet et al. (31) showed that the odds ratios for CAD
were progressively higher with increasing Lp(a) levels in a
Figure 1 - Predicted probabilities of coronary artery disease based on a multivariate-adjusted model. LTA+ means LTA genotype GG.
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large, prospective, population-based cohort that was
adjusted for several established risk factors. Virani et al.
(33) also showed that Lp(a) levels are associated with an
increased risk of cardiovascular diseases in both African
American and Caucasian male and female subjects. Sawage
et al. (34) demonstrated an association between low Lp(a)
levels and all-cause or cancer deaths and similar outcomes
for low and high Lp(a) levels for cardiovascular deaths.
Use of genetic markers in risk prediction for CAD
Few studies have utilized genetic markers of CAD in risk
prediction. Rossouw et al. (35) analyzed 23 inflammatory,
lipid, and thrombotic biomarkers and 8 genetic polymorph-
isms in postmenopausal women (aged 50-79 years) receiv-
ing hormone replacement therapy in a nested case-control
study. Of the 23 biomarkers, the following 13 were
associated with CHD events: interleukin 6, matrix metallo-
proteinase 9, HDL-C, LDL-C, total cholesterol, triglycerides,
D-dimer, factor VIII, von Willebrand factor, leukocyte count,
homocysteine, fasting insulin, and 1 genetic polymorphism
(the glycoprotein IIIa leu33pro mutation). Additive risk
prediction of the biomarkers over the conventional risk
factors was not performed. Ripatti et al. (36) calculated a
genetic risk score based on 13 SNPs and observed an
association with a first coronary heart disease event, but the
genetic risk score did not improve risk prediction compared
with risk prediction based on traditional risk factors and
family history. Paynter et al. (37) calculated a genetic risk
score based on 101 SNPs in 19,313 healthy Caucasian
women who were followed up over a median of 12.3 years
in a prospective study. After adjustment for traditional
cardiovascular risk factors, the genetic risk score was not
associated with cardiovascular disease risk. The LTA gene
mutation was not included in the genetic risk score of the
two previous studies. Thanassoulis et al. (38) showed a
marginal increase in the risk prediction of cardiovascular
events with the genetic risk score in addition to standard
cardiovascular risk factors and a high risk of coronary artery
calcium. However, future studies evaluating the utility of
coronary artery calcium and genetic risk scores in predicting
lifetime risk are needed. Genome-wide single nucleotide
polymorphism association studies have identified several
SNPs that are significantly associated with CAD and with
traditional risk factors for CAD (39-42). However, the results
of all these studies still showed inconsistencies with regard
to the presence of a causal relationship between biomarkers,
with or without the inclusion of genetic markers, and CAD
and traditional risk factors. A mechanistic basis for the
association between SNPs and coronary heart disease
was observed, although the atherosclerotic process was
unknown (43). However, none of the previously mentioned
studies analyzed multiple biomarkers for the prediction of
CAD in young adults aged ,50 years.
In this study, we analyzed several biomarkers related to
thrombogenic and atherogenic processes, and we included
the LTA mutation as a candidate gene approach to risk
assessment. The LTA mutation was frequently associated
with CAD. In our study, the presence of the LTA gene
mutant allele provided incremental information about CAD
risk prediction. Previous case-control and cross-sectional
studies examined the association between LTA gene
polymorphisms and cardiovascular disease, but the results
were inconsistent. The study by Ozaki et al. (17) described
significant associations between LTA gene polymorphisms
and myocardial infarction; however, the authors did not
adjust for relevant covariates, including gender and age,
and the genotype distributions among the control subjects
were not in Hardy-Weinberg equilibrium. The association
between LTA gene polymorphisms and CHD was con-
firmed in another Japanese population and in the family-
based European PROCARDIS (precocious coronary artery
disease) study (44). A significant association was observed
between the LTA C804A genotype and the extent of
coronary atherosclerosis in Caucasian patients with angio-
graphically confirmed coronary atherosclerosis (45).
However, several other studies did not detect an association
between LTA gene polymorphisms and myocardial infarc-
tion (10,14,15). A meta-analysis performed by Clarke et al.
(46) also showed no relationship between LTA gene
polymorphisms and CHD. However, they did not study
the LTA gene polymorphism (rs909253) evaluated in the
Japanese study and our study. The most straightforward
explanation for the findings of our study may be associated
with the genetic differences of studied populations. Among
populations with similar genetic backgrounds, the differ-
ences in allele frequency make it difficult to extrapolate
genetic findings from one population to another. In our
population, we demonstrated an association between LTA
gene polymorphisms and increased risk of well-documen-
ted stable CAD in younger patients aged ,50 years. Genetic
diversity in different populations may be especially relevant
Figure 2 - Receiver operating characteristic (ROC) curves. Model1
included the following variables: gender, hypertension, smok-
ing, diabetes, family history of CAD, dyslipidemia, and body mass
index. Model1 vs. Model1+Lp(a) (p = 0.047); Model1 vs.
Model1+Lp(a)+LTA (p=0.024).
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to the LTA genomic region, which lies within the HLA
region and has an erratic pattern of LD structure, with both
short LD islands and long-range haplotypes (47). In our
study, Lp(a) and LTA mutations alone were associated with
lower risk prediction for CAD compared with conventional
risk factors, but the inclusion of each mutation with
conventional risk factors resulted in a progressive and
statistically significant increase in risk prediction for CAD
(Figure 2). The impact of the increased risk prediction based
on AUC/C-statistics from 0.779 to 0.802 in clinical practice
is uncertain and needs to be confirmed in future studies.
Study limitations
Our study has several limitations. This was a case-control
study, and in such studies, casual associations are frequent
when the sample size is relatively small for the association
analysis of complex diseases with genetic mutations of
multifactorial traits. Additionally, this case-control study
was age-matched but not gender-matched. Therefore, the
clinical and laboratory features observed more often in
women may have influenced the final results. The analysis
of one mutation can lead to results not identified in
prospective studies with a larger number of individuals.
The analysis of a significantly higher number of mutations,
use of better laboratory techniques, and application of more
sophisticated statistical models improved the genetic risk
prediction for CAD. This study examined a significant
number of atherogenic and thrombogenic markers in
patients with premature CAD, but the markers represent a
small portion of those involved in the atherosclerosis
process. The complex interaction between genetic factors
and the environment, including the impact of current
medications on the treatment of CAD, may have further
influenced the data interpretation.
Traditional risk factors played a strong role in risk
prediction for the onset of premature coronary athero-
sclerosis in our population. The inclusion of Lp(a) and LTA
mutations in the set of conventional risk factors showed an
additive but small increase in the risk prediction for
premature CAD.
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